Shopping Cart
- Remove All
Your shopping cart is currently empty
Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $970 | Backorder |
| Description | Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD). |
| In vitro | Zevaquenabant simultaneously inhibits CB1 receptors and iNOS in peripheral organs [1]. |
| In vivo | Zevaquenabant (3 mg/kg; p.o.; for 28 days) significantly enhances renal morphology and function in diet-induced obese mice[1]. Using 6-week-old male C57Bl/6J mice as an animal model for diet-induced obesity[1], the administration of Zevaquenabant markedly improved kidney health and performance. |
| Synonyms | (S)-MRI-1867 |
| Molecular Weight | 547.98 |
| Formula | C25H21ClF3N5O2S |
| Cas No. | 1998760-00-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.